Sort   by:  
 Page size 
ProteomicsPhosphoproteomics analysis of Erk signaling in embryonic stem cell differentiation
Mass spectrometry-based proteomics was applied to unravel Erk signaling in mouse embryonic stem cells (ESCs). A previously described engineered ESCs system for Erk induction via a drug-inducible cRAF-ErT2 fusion (Hamilton, W. B. & Brickman, J. M., Cell Rep 2014) was used in two different setups meas...
ORGANISM(S): Mus musculus (Mouse) 
2019-08-12 | PXD012573 | Pride
Lc-msms Mouse Embryonic stem cells 
ProteomicsProteomics analysis of ALK signaling in neuroblastoma cells
We used mass spectrometry-based proteomics to unravel anaplastic lymphoma kinase (ALK) signaling in the ALK and MYCN amplified neuroblastoma cell line, NB1. We specifically measured the ALK interactome, phosphoproteome, phosphotyrosine interactome and proteome as outlined below. ALK Interactome and ...
ORGANISM(S): Homo sapiens (Human) 
2018-11-21 | PXD006404 | Pride
Lc-msms Neuroblastoma Alk signaling Human 
ProteomicsPhosphoroteomics analysis of ALK signaling in neuroblastoma cells
We used mass spectrometry-based proteomics to unravel anaplastic lymphoma kinase (ALK) signaling in the ALK and MYCN amplified neuroblastoma cell line, NB1. We specifically measured the ALK phosphoproteome upon siRNA depletion of ALK and upon ALK inhibition using the ALK-targeting small-molecule inh...
ORGANISM(S): Homo sapiens (Human) 
2018-11-21 | PXD009477 | Pride
Lc-msms Neuroblastoma Alk signaling Human 
ProteomicsPhosphoproteomics of in vivo resistance to EGFR-targeted therapy in lung cancer cells
Mass spectrometry-based quantitative proteomics profiling of in vivo signaling changes in 41 therapy resistant (osimertinib or EGFR/Met bispecific antibody treament) tumors from four xenograft NSCLC models.
ORGANISM(S): Homo sapiens (Human) 
2017-08-28 | PXD006114 | Pride
Tyrosine phosphorylation Xenografts Nsclc Mass spectrometry Drug resistance Egfr 
ProteomicsProteomics analysis of synergistic drug combination of midostaurin and BMS-754807 in Ewing sarcoma ASP14 cell line
We used quantitative mass spectrometry-based proteomics to unravel global changes in the phosphoproteome upon treatment of ASP14 cells (a Ewing Sarcoma cell line) according to the setup below. The combination of drugs were experimentally shown to infer synergy in terms of cell killing. Three experim...
ORGANISM(S): Homo sapiens (Human) 
2017-04-19 | PXD002765 | Pride
Human Lc-msms Drug synergy Ewing sarcoma 
ProteomicsProteomics of NGF-TrkA signaling dynamics in neuroblastoma cells
We used quantitative mass spectrometry-based proteomics to unravel global nerve growth factor (NGF)-induced TrkA signaling dynamics at the interactome, phosphoproteome and proteome level. A tetracycline-inducible system for TrkA expression was generated in the human neuroblastoma cell line, SH-SY5Y....
ORGANISM(S): Homo sapiens (Human) 
2015-05-06 | PXD001115 | Pride
Neuroblastoma Phosphoproteome Mass spectrometry Silac Ngf Proteome Trka Interactome 
ProteomicsProteome analysis of NGF stimulated PC12 cells
We used quantitative mass spectrometry-based proteomics to unravel global nerve growth factor (NGF)-induced changes in protein abundance using the rat PC12 cell line. Cells were stimulated with NGF for 0, 24 and 48 h in a triple SILAC setup (Light: Lys0,Arg0; Medium: Lys4,Arg6; and Heavy: Lys8,Arg10...
ORGANISM(S): Rattus norvegicus (Rat) 
2015-05-06 | PXD001478 | Pride
Rat Q exactive Lc-ms/ms 
ProteomicsSpatial proteomics of selinexor, MK-2206 and combination response in AML cells
In order to characterize the dynamics of proteins between different cellular compartments in response to selinexor (XPO1 inhibitor), MK-2206 (Akt inhibitor) an the combination i AML cells, we treated MV4-11 and PL-21 cells for 6 hours with DMSO, 1 uM selinexor, 1 uM MK-2206 or the combination. Each...
ORGANISM(S): Homo sapiens (Human) 
2022-08-07 | PXD033527 | Pride
Human Spatial proteomics Aml Lc-ms/ms 
ProteomicsSingle-shot proteome of AML cell lines and AML ex vivo cells upon selinexor treatment
Single-shot proteome analysis of 4 AML cell lines; 2 selinexor sensitive cell lines (GDM-1, MV4-11) and 2 resistant cell lines (NOMO-1 and PL-21) and ex vivo AML cells from 30 patients treated with DMSO (B; before treatment) or 1 uM selinexor (A; after treatment) for 6 hours.
ORGANISM(S): Homo sapiens (Human) 
2022-08-07 | PXD033515 | Pride
Human Lc-msms Aml 
ProteomicsPhosphoproteomics analysis of Selinexor response in AML ex vivo patient samples and cell lines
We used mass spectrometry-based proteomics to perform a phosphoproteomics analysis of selinexor-treated ex vivo AML patient samples (n=20) and 4 AML cell lines (PL-21, NOMO-1, GDM-1 and MV4-11). For quantitative phosphoproteomics, we used a tandem mass tag (TMT)-based approach. Conditions for the TM...
ORGANISM(S): Homo sapiens (Human) 
2022-08-07 | PXD017660 | Pride
Lc-msms Selinexor Human Aml 
Sort   by:  
 Page size